Medtronic has more positive transcatheter heart valve data
Medtronic (NYSE: MDT) today announced the release of new data for its transcatheter heart valve therapy technologies.
Stay updated with breaking news from Howardc Herrmann. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Medtronic (NYSE: MDT) today announced the release of new data for its transcatheter heart valve therapy technologies.
A head-to-head trial of two widely used TAVR devices in patients with small aortic annuli, mostly women, showed differences in performance at 1 year in the SMART trial.
First head-to-head comparison of leading valve types finds better valve performance with selfexpanding valve and non-inferior clinical outcomes at one year
People with a small aortic annulus, a part of the heart's anatomy where the left ventricle meets the aorta, who underwent transcatheter aortic valve replacement (TAVR) with a supra-annular self-expanding valve saw similar clinical outcomes and superior valve performance at one year compared with those who underwent TAVR with a balloon-expandable valve, according to research presented at the American College of Cardiology's Annual Scientific Session.
New data from largest head-to-head randomized control TAVR trial demonstrates non-inferior clinical outcomes and superior valve performance for Evolut TAVR compared to Sapien™ at one year DUBLIN...